文献速递免疫规划卫生政策与健康促进传染病防控与疫情报告

尽早接种首款可用新冠疫苗的临床与经济价值

The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine.
PubMed 文献 · Am J Prev Med · 2021-01-19

该研究于2020年构建模拟美国人群、新冠传播及不同效力与接种时机疫苗的计算模型,评估接种的临床与经济价值。结果显示,除大流行早期少数情境外,等待更高效力疫苗反而增加住院与成本;

要点

  • 除大流行早期少数情境外,等待更高效力疫苗会增加住院和成本。

核心结论

  • 相对较少情境下值得放弃首款可用新冠疫苗去等待 later 更高效力疫苗,即使后者效力明显更高。

研究设计与样本

  • 2020年开发计算模型,模拟美国人群、新冠传播及不同效力(防感染或减少重症)和接种时机的疫苗,估算接种的临床与经济价值。

主要发现

  • 除大流行早期少数情境外,首款疫苗可用时等待更高效力疫苗会导致大流行期间更多住院和成本。

临床怎么用

  • 公共卫生决策中,首款可用新冠疫苗通常应尽早接种,而非等待更高效力疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: During a pandemic, there are many situations in which the first available vaccines may not have as high effectiveness as vaccines that are still under development or vaccines that are not yet ready for distribution, raising the question of whether it is better to go with what is available now or wait. METHODS: In 2020, the team developed a computational model that represents the U.S. population, COVID-19 coronavirus spread, and vaccines with different possible efficacies (to prevent infection or to reduce severe disease) and vaccination timings to estimate the clinical and economic value of vaccination. RESULTS: Except for a limited number of situations, mainly early on in a pandemic and for a vaccine that prevents infection, when an initial vaccine is available, waiting for a vaccine with a higher efficacy results in additional hospitalizations and costs over the course of the pandemic. For example, if a vaccine with a 50% efficacy in preventing infection becomes available when 10% of the population has already been infected, waiting until 40% of the population are infected for a vaccine with 80% efficacy in preventing infection results in 15.6 million additional cases and 1.5 million additional hospitalizations, costing $20.6 billion more in direct medical costs and $12.4 billion more in productivity losses. CONCLUSIONS: This study shows that there are relatively few situations in which it is worth foregoing the first COVID-19 vaccine available in favor of a vaccine that becomes available later on in the pandemic even if the latter vaccine has a substantially higher efficacy.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Bartsch SM, O'Shea KJ, Wedlock PT, et al. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021. PMID: 33632650. doi:10.1016/j.amepre.2021.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。